TD Cowen Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,200.00

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target hoisted by TD Cowen from $1,030.00 to $1,200.00 in a research report report published on Tuesday, Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on REGN. Truist Financial reissued a […]

Leave a Reply

Your email address will not be published.

Previous post SolarEdge Technologies (NASDAQ:SEDG) PT Raised to $29.00
Next post Bank of America Cuts Autoliv (NYSE:ALV) Price Target to $133.00